Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada

At a threshold of CA$200,000/QALY, dabrafenib is unlikely to be cost effective compared with dacarbazine. It is not possible to make reliable conclusions regarding the relative cost effectiveness of dabrafenib versus vemurafenib based on available information. </AbstractSection> Copyright Springer International Publishing Switzerland 2015

MoreLess

Year of publication:	2015
Authors:	Delea, Thomas ; Amdahl, Jordan ; Wang, Alice ; Amonkar, Mayur ; Thabane, Marroon
Published in:	PharmacoEconomics. - Springer, ISSN 1170-7690. - Vol. 33.2015, 4, p. 367-380
Publisher:	Springer

Online Resource

Check full text access |

More access options

Check Google Scholar

In libraries world-wide (WorldCat)

In German libraries (KVK)

subito order

I need help

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10011241576